Learn from Panos Zalmas, DPhil from the Wellcome Sanger Institute as he presents:
"From CRISPR screening to therapeutics: how orthogonal validation can aid the discovery of novel drug targets"
Panos Zalmas leads the Open Targets Validation Lab at the Wellcome Sanger Institute, UK. The lab is a core capability of the Open Targets Consortium, an innovative public-private partnership that uses human genetics and genomics data for systematic drug target identification and prioritization. The aim of the Validation Lab is to improve the chances of target adoption into drug discovery pipelines, by providing an independent source of in silico triage, orthogonal experimental validation and mechanistic characterization of therapeutic candidates emerging from target identification programs across multiple therapy areas, such as oncology and neurodegeneration.
Learn about Horizon's RNAi libraries and screening services